For example,Enbrel(etanercept) orHumira(adalimumab) are referred to as “large-molecule” drugs because they are larger and more complex in structure than small-molecule drugs (like ibuprofen). Biologic products are very expensive, often in the tens-of-thousands of dollars per year, due to cost...
Trends in Annual Out-of-Pocket (OOP) Spending for Biologic Drugs, Before and After Biosimilar Availability View LargeDownload All OOP costs are compared with costs in the year before biosimilar competition entered the market (year −1). The average for all drugs was determined by a mixed ...
Drug PricingBiosimilars are close copies of biologic drugs, a group of complex pharmaceutical products that cannot be exactly replicated. The United States Congress passedMaini, LucaFeng, JoshHwang, ThomasKlimek, JacobSocial Science Electronic Publishing...
Biologic drugs have revolutionized the treatment of psoriasis and other chronic inflammatory diseases. In recent years, numerous biosimilar molecules that target cytokines such as TNF-alpha or its receptors have been developed. The approval of biosimilars has made it possible to reduce the costs of b...
More information:Kimberly Feng et al, Patient Out-of-Pocket Costs for Biologic Drugs After Biosimilar Competition,JAMA Health Forum(2024).DOI: 10.1001/jamahealthforum.2023.5429 Andrew W. Mulcahy, Revisiting Expectations of US Biosimilars—Panacea or One Piece of the Puzzle?,JAMA Health Forum(2024)...
(CT-P47, tocilizumab). This significant milestone reflects the company’s leadership in biosimilar innovation and commitment to expanding access to biologic treatments across Europe. Eydenzelt (40 mg/mL solution for injection in vial and pre-filled syringe), a biosimilar to Eylea ® (aflibercept...
Biosimilars are biologic drugs that are highly similar to a licensed (i.e., originator or reference) biologic product.15–17 To receive regulatory approval, a proposed biosimilar product must show no clinically meaningful differences in safety, purity or potency compared with the originator biologic,...
In addition to infographics and charts depicting the differing biosimilar and biologic development processes, the industry has now begun churning out visual aids highlighting the major players in the supply chain and the passage of money amongst them and revenues made. The FTC workshop brought ...
In addition to infographics and charts depicting the differing biosimilar and biologic development processes, the industry has now begun churning out visual aids highlighting the major players in the supply chain and the passage of money amongst them and revenues made. The FTC workshop brought ...
MYL-1701P, formerly developed globally by Mylan Inc (now Viatris Inc) and Momenta Pharmaceuticals Inc (now part of Johnson & Johnson) and currently by Biocon Biologics Inc, recently received FDA approval as an interchangeable biosimilar drug to the reference biologic aflibercept for use in ...